Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: February 13, 2008
Last updated: May 31, 2012
Last verified: February 2011
This study is being conducted to provide safety, tolerability, PK and PD data in repeat dosing that will allow further studies with darapladib in Japanese patients

Condition Intervention Phase
Drug: SB-480848 (Darapladib)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase I Study of SB-480848 (Darapladib) -A Double Blind, Randomised, Placebo-controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-480848 in Healthy Japanese Male Subjects-

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Safety/tolerability of repeat oral doses of darapladib
  • Primary Pharmacokinetic parameters of repeat oral doses of darapladib

Secondary Outcome Measures:
  • -Secondary PK parameters
  • Tmax, and t1/2 of SB-480848 and AUC, Cmax, t1/2 and Tmax of the pharmacologically active metabolite SB-553253 (as data permit)
  • Plasma Lp-PLA2 activity, expressed in terms of percent inhibition relative to baseline
  • Estimation of PK/PD parameters and their associated variability, appropriate to the final models
  • -PK parameters of SB553253
  • -description of plasma concentration-Lp-PLA2 activity inhibition relationship after repeat oral doses of darapladib. all measured same timepoints as primary
  • -inhibition of Lp-PLA2 activity

Estimated Enrollment: 18
Study Start Date: January 2008
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 64 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Healthy Japanese adult males between 20 and 64 yeas of age, inclusive.
  • Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-lead ECG, immunology tests and urinary drug screen test.
  • Bodyweight >50 kg and body mass index (BMI) between 18.5 and 25.0 at screening.
  • Subjects must be capable of providing written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Baseline QTc interval <450 msec.
  • Non-smoker or ex-smoker having ceased smoking for at least 6 months.
  • Clinical laboratory examination (AST, ALT, ALP and GGT) at screening are within the normal range.
  • The subject is able to attend all visits and complete the study.

Exclusion criteria:

  • Any clinically relevant abnormality identified on the screening physical examination, vital sign measurement, 12-lead ECG recording and/or clinical laboratory examination that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern.
  • History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.
  • Positive for urine drug at screening.
  • Positive for syphilis, HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody or HTLV-1 antibody at screening.
  • Use of prescription or no-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
  • Consumption of grapefruit juice or food within 7 days prior to the first dose of study medication.
  • A history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology.
  • Donation of blood in excess of 400mL within 4 months or 200mL within 1 months prior to at screening.
  • History of drug abuse, or current conditions of drug abuse or alcoholism.
  • Participation in a clinical study or post-marketing study with an investigational or a non-investigational product or device within 4 months of preceding the first dose of study medication.
  • Participation in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device.
  • History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses.
  • The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00622830

GSK Investigational Site
Ibaraki, Japan, 305-0856
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00622830     History of Changes
Other Study ID Numbers: LPL110736 
Study First Received: February 13, 2008
Last Updated: May 31, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by GlaxoSmithKline:
Japanese healthy volunteers

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Phospholipase A2 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016